Literature DB >> 34472094

Which adults with sickle cell disease need an evaluation for pulmonary embolism?

Nadirah El-Amin1, Steven D Lauzon2, Paul J Nietert3, Julie Kanter4.   

Abstract

Individuals living with sickle cell disease (SCD) are at an increased risk of venous thrombo-embolism (VTE) including pulmonary embolisms (PEs). There is a high mortality associated with PE in individuals with SCD. It can be difficult to diagnose PE since presenting symptoms of PE often mimic those of other forms of vaso-occlusive crisis in SCD. Currently, there are no validated models for predicting PEs in patients with sickle cell disease, which often leads to frequent CT scans and exposure to harmful radiation and intravenous contrast. The aim of this study was to evaluate different host variables and potential clinical biomarkers of patients with SCD including those used in the Wells score to assess predictability for PE in order to create a more accurate diagnostic algorithm to predict PE. A retrospective chart review was performed on 349 patients with SCD who underwent testing for a PE with a CT scan of the chest. Forward and backward stepwise model selection was performed to obtain a parsimonious model of the predictors of PEs. The incidence of PE in this population was 9·7%. Of the factors evaluated for this study, the Wells score was the only one with clinical significance. A Wells score greater than 4 had a sensitivity and specificity of 72·5% and 70·1%, respectively, and a score greater than 6 had a sensitivity and specificity of 50% and 87%, respectively. The Wells score is an acceptable clinical tool which may prove useful in individuals with SCD to predict who is most likely to have a PE and therefore should undergo a CT scan. A prospective study is needed to further confirm these findings.
© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  Wells score; computed tomography; pulmonary embolism; sickle cell disease; venous thromboembolism

Mesh:

Year:  2021        PMID: 34472094      PMCID: PMC8693334          DOI: 10.1111/bjh.17552

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  34 in total

1.  Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.

Authors:  J Kurantsin-Mills; F A Ofosu; T K Safa; R S Siegel; L S Lessin
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

Review 2.  Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis.

Authors:  Jun-Hua Shen; Hong-Lin Chen; Jian-Rong Chen; Jia-Li Xing; Peng Gu; Bao-Feng Zhu
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

3.  Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.

Authors:  P S Wells; D R Anderson; M Rodger; J S Ginsberg; C Kearon; M Gent; A G Turpie; J Bormanis; J Weitz; M Chamberlain; D Bowie; D Barnes; J Hirsh
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

4.  Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease.

Authors:  D V Devine; T R Kinney; P F Thomas; W F Rosse; C S Greenberg
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

5.  Selective coronary angiography. Report of a fatality in a patient with sickle cell hemoglobin.

Authors:  J D McNair
Journal:  Calif Med       Date:  1972-11

Review 6.  Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis.

Authors:  E Ceriani; C Combescure; G Le Gal; M Nendaz; T Perneger; H Bounameaux; A Perrier; M Righini
Journal:  J Thromb Haemost       Date:  2010-02-02       Impact factor: 5.824

7.  Hemolytic anemia associated with a radiopaque contrast agent in a patient with hemoglobin SC disease.

Authors:  M Darr; S Hamburger; B Koprivica; E Ellereck
Journal:  South Med J       Date:  1981-12       Impact factor: 0.954

8.  Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism.

Authors:  Stephen J Wolf; Tracy R McCubbin; Kim M Feldhaus; Jeffrey P Faragher; Dorothy M Adcock
Journal:  Ann Emerg Med       Date:  2004-11       Impact factor: 5.721

9.  Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease.

Authors:  B Nsiri; N Gritli; F Bayoudh; T Messaoud; S Fattoum; S Machghoul
Journal:  Hematol Cell Ther       Date:  1996-07

10.  Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls.

Authors:  D Hagger; S Wolff; J Owen; D Samson
Journal:  Blood Coagul Fibrinolysis       Date:  1995-04       Impact factor: 1.276

View more
  1 in total

1.  Confirmation of the utility of the Wells' Score for pulmonary embolism in patients with sickle cell disease.

Authors:  Jori E May; Steven D Lauzon; Richard C Godby; Julie Kanter
Journal:  J Thromb Thrombolysis       Date:  2022-04-19       Impact factor: 5.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.